COMP <GO>
ANL vs LXRX // REVENUE GROWTH (YOY)
Adlai Nortye Group Ltd. (NASDAQ) VS. Lexicon Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: ANL 2
— LXRX 0
■ METRIC PARITY
LAST: $10.28 (+0.78%) • MKT CAP: $662.0M
revenue-growth
—
LAST: $1.48 (-0.34%) • MKT CAP: $658.5M
revenue-growth
180.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ANL VS. LXRX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ANL | LXRX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 96.00% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | -31.50% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -10.30% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | 180.00% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 5/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 31.6 | 29.1 | +2.51 | ANL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $662.0M | $658.5M | $3.5M | ANL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ANL REV | LXRX REV | ANL GROSS % | LXRX GROSS % | ANL FCF | LXRX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $49.8M | — | 98.0% | — | -$67.9M |
| FY 2024 | — | $6.0M | — | 89.7% | — | -$179.8M |
| FY 2023 | — | $1.1M | — | — | — | -$161.9M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ANL // BETA —
LXRX // BETA —